tiprankstipranks
Trending News
More News >
Pyxis Oncology (PYXS)
NASDAQ:PYXS
US Market

Pyxis Oncology (PYXS) AI Stock Analysis

Compare
459 Followers

Top Page

PY

Pyxis Oncology

(NASDAQ:PYXS)

Rating:47Neutral
Price Target:
Pyxis Oncology's score reflects ongoing financial challenges with significant cash burn and unprofitability. While there are positive developments with the strategic focus on its lead candidate, technical indicators suggest caution. Valuation remains unattractive due to negative earnings. The company's future hinges on successful execution of its strategic initiatives.
Positive Factors
Clinical Progress
New preclinical data support broad anti-tumor activity.
Market Opportunity
The company is exploring treatment options for patients who have relapsed on certain therapies, which could represent an underappreciated market opportunity.
Strategic Focus
The assumption of CMO duties by CEO Lara Sullivan is seen as a strategic move to enhance focus and efficiency in clinical execution.
Negative Factors
Competitive Landscape
The competitive landscape for PYXS includes mature data from other companies that will inform PYXS's next steps and set high benchmarks for comparison.
Financial Challenges
Net loss of $21.2 million, or a loss of $0.35 per share, was comparable to the projected loss, indicating financial challenges.

Pyxis Oncology (PYXS) vs. SPDR S&P 500 ETF (SPY)

Pyxis Oncology Business Overview & Revenue Model

Company DescriptionPyxis Oncology, Inc. (PYXS) is a biopharmaceutical company focused on developing novel antibody-drug conjugates (ADCs) and immuno-oncology therapeutics for the treatment of cancer. The company operates within the healthcare sector, primarily targeting oncology as its core field. Pyxis Oncology aims to address unmet medical needs by leveraging its proprietary platforms to discover and develop innovative therapies that improve patient outcomes.
How the Company Makes MoneyPyxis Oncology generates revenue through a combination of research and development collaborations, licensing agreements, and potential milestone payments from strategic partnerships with other pharmaceutical companies. The company's business model is largely reliant on advancing its pipeline of oncology therapeutics through clinical trials, securing regulatory approvals, and ultimately commercializing these products either independently or through collaborators. Revenue streams may also include upfront payments and royalties from licensing its technologies and products to other companies in the pharmaceutical industry. The success of Pyxis Oncology's revenue model depends on its ability to successfully develop and market its therapeutic candidates, as well as forming beneficial partnerships that enhance its product offerings and market reach.

Pyxis Oncology Financial Statement Overview

Summary
Pyxis Oncology is at a critical growth stage, with efforts to generate revenue, yet profitability remains elusive. Financial stability is supported by cash reserves, but negative cash flows and equity challenges pose significant risks. The company may need strategic actions to achieve sustainable financial health.
Income Statement
35
Negative
Pyxis Oncology's income statement shows a recent introduction of revenue, yet the company remains unprofitable with persistent negative net income. The negative EBIT and EBITDA margins indicate ongoing operational challenges, although gross profit margin has improved due to revenue generation.
Balance Sheet
45
Neutral
The balance sheet reveals high equity levels but also significant liabilities, resulting in a moderate debt-to-equity ratio. The company has a substantial cash position, yet the negative stockholder's equity in earlier years and recent reduction in equity suggest financial vulnerabilities.
Cash Flow
40
Negative
Cash flow analysis indicates negative free cash flow and operating cash flow, highlighting cash burn issues. There is some improvement in financing cash flow, yet the reliance on external funding is evident. The free cash flow to net income ratio remains unfavorable.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
16.15M0.000.000.000.00
Gross Profit
15.67M-2.00M-1.84M-1.25M-444.00K
EBIT
-89.46M-82.20M-123.48M-69.72M-12.89M
EBITDA
-65.51M-78.49M-122.77M-69.07M-12.43M
Net Income Common Stockholders
-77.33M-73.79M-117.95M-81.54M-12.76M
Balance SheetCash, Cash Equivalents and Short-Term Investments
126.93M119.30M179.29M274.74M8.08M
Total Assets
157.18M173.73M211.38M280.02M10.15M
Total Debt
20.20M21.33M18.92M165.00K780.00K
Net Debt
727.00K11.67M-160.37M-274.57M-7.30M
Total Liabilities
36.43M48.02M50.55M18.71M25.80M
Stockholders Equity
120.75M125.70M160.82M261.31M-15.64M
Cash FlowFree Cash Flow
-57.91M-77.44M-95.73M-35.87M-11.57M
Operating Cash Flow
-57.67M-70.71M-89.33M-35.33M-10.08M
Investing Cash Flow
8.15M-104.85M-6.40M-590.00K-1.48M
Financing Cash Flow
59.33M5.93M183.00K304.04M35.00K

Pyxis Oncology Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.23
Price Trends
50DMA
1.07
Positive
100DMA
1.23
Positive
200DMA
2.20
Negative
Market Momentum
MACD
0.04
Negative
RSI
58.42
Neutral
STOCH
87.88
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PYXS, the sentiment is Positive. The current price of 1.23 is above the 20-day moving average (MA) of 1.15, above the 50-day MA of 1.07, and below the 200-day MA of 2.20, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 58.42 is Neutral, neither overbought nor oversold. The STOCH value of 87.88 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PYXS.

Pyxis Oncology Risk Analysis

Pyxis Oncology disclosed 83 risk factors in its most recent earnings report. Pyxis Oncology reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Pyxis Oncology Peers Comparison

Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
53
Neutral
$5.14B3.23-45.01%2.85%17.55%-0.69%
MGMGX
50
Neutral
$60.56M-31.93%-4.22%18.67%
47
Neutral
$76.20M-66.30%30.51%
42
Neutral
$82.03M-38.04%
39
Underperform
$88.80M-73.85%-40.59%
37
Underperform
$40.60M678.24%-69.59%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PYXS
Pyxis Oncology
1.24
-2.50
-66.84%
AVTX
Avalo Therapeutics
3.62
-7.89
-68.55%
CABA
Cabaletta Bio
1.74
-8.93
-83.69%
ANRO
Alto Neuroscience, Inc.
2.87
-9.41
-76.63%
MGX
Metagenomi, Inc.
1.66
-4.76
-74.14%

Pyxis Oncology Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Pyxis Oncology Highlights Strategic Focus on Lead Candidate
Positive
Mar 24, 2025

On March 24, 2025, Pyxis Oncology updated its corporate presentation, highlighting its focus on advancing its lead product candidate, micvotabart pelidotin, for treating recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The company is positioning itself as a differentiated ADC company with a strong cash runway and multiple clinical data catalysts expected in 2025 and 2026. This strategic focus aims to address significant unmet needs in the R/M HNSCC treatment landscape, potentially enhancing Pyxis Oncology’s position in the oncology sector.

Executive/Board ChangesBusiness Operations and Strategy
Pyxis Oncology Announces CMO Resignation and New Trials
Neutral
Mar 18, 2025

On March 18, 2025, Pyxis Oncology announced the resignation of Ken Kobayashi, M.D., as Chief Medical Officer, with Lara S. Sullivan, M.D., assuming the role alongside her current duties as President and CEO. The company also reported positive preliminary data from its Phase 1 trial of micvotabart pelidotin, receiving Fast Track Designation from the FDA for treating certain head and neck cancers, and initiated further clinical trials, including a combination study with Merck’s KEYTRUDA®. Pyxis Oncology has streamlined its operations, reducing its workforce by 20% to focus on advancing the MICVO clinical program, and expects its cash runway to extend into the second half of 2026.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.